Literature DB >> 7910756

Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication.

D Glovinsky1, K T Kalogeras, D G Kirch, R Suddath, R J Wyatt.   

Abstract

Cerebrospinal fluid (CSF) oxytocin concentrations in 20 neuroleptic-treated schizophrenic patients, 31 neuroleptic-withdrawn schizophrenic patients, and 15 normal control subjects were compared. Neither within-subject comparisons of CSF oxytocin concentration measurements made during neuroleptic treatment and withdrawal (n = 11), nor comparison of the combined neuroleptic-withdrawn and neuroleptic-treated patient group (n = 40) with control subjects (n = 15) differed significantly, suggesting that CSF oxytocin concentration is not altered in schizophrenia.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7910756     DOI： 10.1016/0920-9964(94)90021-3

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


  26 in total

1.  Reduced DNA Methylation of the Oxytocin Receptor Gene Is Associated With Anhedonia-Asociality in Women With Recent-Onset Schizophrenia and Ultra-high Risk for Psychosis.

Authors:  Minji Bang; Jee In Kang; Se Joo Kim; Jin Young Park; Kyung Ran Kim; Su Young Lee; Kyungmee Park; Eun Lee; Seung-Koo Lee; Suk Kyoon An
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

Review 2.  The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings.

Authors:  David M Cochran; Daniel Fallon; Michael Hill; Jean A Frazier
Journal:  Harv Rev Psychiatry       Date:  2013 Sep-Oct       Impact factor: 3.732

Review 3.  Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.

Authors:  Ellen R Bradley; Joshua D Woolley
Journal:  Neurosci Biobehav Rev       Date:  2017-05-12       Impact factor: 8.989

4.  Plasma oxytocin immunoreactive products and response to trust in patients with social anxiety disorder.

Authors:  Elizabeth A Hoge; Elizabeth A Lawson; Christina A Metcalf; Aparna Keshaviah; Paul J Zak; Mark H Pollack; Naomi M Simon
Journal:  Depress Anxiety       Date:  2012-07-17       Impact factor: 6.505

5.  Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.

Authors:  Kai Macdonald; David Feifel
Journal:  Acta Neuropsychiatr       Date:  2011-12-19       Impact factor: 3.403

6.  Social motivation in schizophrenia: The impact of oxytocin on vigor in the context of social and nonsocial reinforcement.

Authors:  Daniel Fulford; Michael Treadway; Joshua Woolley
Journal:  J Abnorm Psychol       Date:  2018-01

Review 7.  Neurobiology of sociability.

Authors:  Heather K Caldwell
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

8.  Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia.

Authors:  Mary R Lee; Heidi J Wehring; Robert P McMahon; Fang Liu; Jared Linthicum; Joseph G Verbalis; Robert W Buchanan; Gregory P Strauss; Leah H Rubin; Deanna L Kelly
Journal:  Schizophr Res       Date:  2016-02-12       Impact factor: 4.939

9.  The Neurobiological Basis for Social Affiliation in Autism Spectrum Disorder and Schizophrenia.

Authors:  Amanda Crider; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2016-04-16

Review 10.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.